NEW YORK, November 27, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members
with timely information WallStEquities.com has issued free tailored
Stock Review on ADXS, GRFS, JUNO, and LXRX which is a click away at
http://www.wallstequities.com/registration. For today,
WallStEquities.com concentrates on the Biotechnology industry,
which consists of companies that are engaged in the research and
development of new drugs, medical devices, and
procedures. Equities under evaluation this morning are:
Advaxis Inc. (NASDAQ: ADXS), Grifols S.A. (NASDAQ: GRFS), Juno
Therapeutics Inc. (NASDAQ: JUNO), and Lexicon Pharmaceuticals Inc.
(NASDAQ: LXRX). Wall St. Equities has a wide array of free research
reports which include today's stock picks, register now to access
them at:
http://www.wallstequities.com/registration
Advaxis
Princeton, New Jersey-based
Advaxis Inc.'s shares recorded a trading volume of 257,715 shares
last Friday. The stock finished the trading session 3.18% lower at
$3.04. The Company's shares are
trading below their 50-day moving average by 20.86%. Furthermore,
shares of Advaxis, which focuses on the discovery, development, and
commercialization of Lm-LLO cancer immunotherapies in the US, have
a Relative Strength Index (RSI) of 39.12.
On November 01st, 2017,
Advaxis has received approval for a $4.8
million tax credit from the New Jersey Economic Development
Authority's New Jersey Technology Business Tax Certificate Transfer
program. The Company anticipates that it will be able to transfer
this credit and receive $4.5 million
in cash by the end of 2017. Follow the link below to your free
research report on ADXS at:
http://www.wallstequities.com/registration/?symbol=ADXS
Grifols
On Friday, Barcelona, Spain
headquartered Grifols S.A.'s stock ended the session 0.35% higher
at $23.12. A total volume of 185,497
shares was traded. The Company's shares have gained 8.44% in the
last one month, 12.84% over the previous three months, and 43.87%
on an YTD basis. The stock is trading 5.28% above its 50-day moving
average and 12.60% above its 200-day moving average. Moreover,
shares of Grifols, which develops, manufactures, and distributes a
range of plasma derivative products primarily in the European
Union, Spain, the US, Canada, and internationally, have an RSI of
56.18.
On October 31st, 2017,
research firm Citigroup initiated a 'Buy' rating on the Company's
stock. The free technical report on GRFS can be accessed at:
http://www.wallstequities.com/registration/?symbol=GRFS
Juno Therapeutics
Seattle, Washington
headquartered Juno Therapeutics Inc.'s stock ended the day 4.18%
higher at $62.85 with a total trading
volume of 1.27 million shares. The Company's shares have
skyrocketed 45.96% in the last month, 104.52% over the previous
three months, and 233.42% on an YTD basis. The stock is trading
30.84% and 96.95% above its 50-day and 200-day moving averages,
respectively. Additionally, shares of Juno Therapeutics, which
engages in developing cell-based cancer immunotherapies, have an
RSI of 72.89.
On November 02nd, 2017,
research firm SunTrust upgraded the Company's stock rating from
'Hold' to 'Buy'.
On November 06th, 2017,
Juno Therapeutics announced that it will present at the
Evercore ISI Biopharma Catalyst / Deep Dive Conference on
November 29th, 2017, at
8:45 a.m. ET. The presentation, which
will feature a business overview and update by Steve Harr, CFO and Head of Corporate
Development, will be webcast and accessible under the Investor
Relations page of the Company's website. Sign up for free on
Wall St. Equities and claim the latest report on JUNO at:
http://www.wallstequities.com/registration/?symbol=JUNO
Lexicon Pharmaceuticals
Shares in The Woodlands, Texas
headquartered Lexicon Pharmaceuticals Inc. recorded a trading
volume of 337,670 shares. The stock ended Friday's session flat at
$9.75. The Company's shares are
trading below their 50-day moving average by 11.45%. Furthermore,
shares of Lexicon Pharma, which focuses on the development and
commercialization of pharmaceutical products for the treatment of
human diseases, have an RSI of 43.37.
On November 08th, 2017,
Lexicon Pharma reported financial results for the three months
ended September 30th, 2017. Revenues for Q3
2017 decreased to $26.9 million; R&D expenses
decreased to $39.1 million; selling, general and
administrative expenses increased to $16.7 million; and
net loss was $30.7 million. As of September
30th, 2017, the Company had $196.8 million in
cash and investments. See the free research coverage on LXRX
at:
http://www.wallstequities.com/registration/?symbol=LXRX
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. WSE has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
WSE has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a credentialed financial analyst [for further information on
analyst credentials, please email info@wallstequities.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by WSE. WSE is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. WSE, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, WSE, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither WSE nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company, we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore
228
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Wall St. Equities